Soru

Zorluk: OrtaPreventive Care and Immunizations

An adolescent girl, aged 1717 years, comes to the outpatient office for a pre-college physical examination. She plans to move into a university dormitory next month. The patient has a history of perinatally acquired human immunodeficiency virus (HIV) infection. Her adherence to antiretroviral therapy has been poor over the past year. She currently feels well and reports no fever, cough, or weight loss. Her temperature is 37.1∘C37.1^{\circ}\text{C} (98.8∘F98.8^{\circ}\text{F}), blood pressure is 110/70 mmHg110/70 \text{ mmHg}, and pulse is 78/min78/\text{min}. Physical examination is notable for white plaques on the buccal mucosa that can be scraped off with a tongue depressor, as well as generalized non-tender lymphadenopathy. Laboratory studies show a CD4+ T-cell count of 140 cells/mm3140 \text{ cells/mm}^3 and an HIV viral load of 150,000 copies/mL150,000 \text{ copies/mL}. A review of her immunization records shows she received all recommended primary vaccines during infancy but has not received any immunizations since 44 years of age. Which of the following vaccines is contraindicated for this patient during today's visit?

  1. A
    Human papillomavirus vaccine
  2. Measles-mumps-rubella vaccineCevap
  3. C
    Meningococcal conjugate vaccine
  4. D
    Pneumococcal conjugate vaccine
  5. E
    Tetanus-diphtheria-acellular pertussis vaccine

Cevap

The measles-mumps-rubella (MMR) vaccine is contraindicated due to the patient's severe immunosuppression.
The measles-mumps-rubella vaccine is a live-attenuated viral vaccine. In patients with severe cellular immunodeficiency, such as this patient with HIV and a CD4+ T-cell count less than 200 cells/mm^3 (along with opportunistic oral candidiasis), live vaccines are absolutely contraindicated. Administration can result in severe, disseminated, and potentially fatal infection from the vaccine strains. This patient should only receive inactivated, recombinant, or toxoid vaccines until her CD4+ count improves to an acceptable level with antiretroviral therapy.

Adım Adım Çözüm

1
Assess the patient's current immune status based on her clinical presentation and laboratory findings.
The patient has poorly controlled HIV with opportunistic oral candidiasis (thrush) and a CD4+ T-cell count of 140 cells/mm^3, indicating severe immunosuppression.
Determining the degree of immunosuppression is mandatory before administering vaccines, as severe immunodeficiency alters vaccine safety protocols.
2
Determine the safety profile of live-attenuated versus inactivated vaccines for this specific patient.
Live-attenuated vaccines are contraindicated in patients with severe immunosuppression (CD4+ count less than 200 cells/mm^3) due to the risk of uncontrolled replication of the vaccine strain.
A severely compromised cellular immune system cannot properly regulate live vaccine viruses, potentially leading to fatal disseminated infection.
3
Identify which of the listed vaccines is a live-attenuated formulation.
The measles-mumps-rubella vaccine is live-attenuated. The other listed options are inactivated, recombinant, or toxoid vaccines.
Distinguishing between vaccine types allows for the correct identification of the contraindicated immunization.

Anahtar Kavram

Live-attenuated vaccines (e.g., measles-mumps-rubella, varicella) are absolutely contraindicated in patients with severe cellular immunosuppression, such as HIV-positive patients with a CD4+ cell count less than 200 cells/mm^3.
Bu soruyu puanla